Fair value (multi-method)
Four independent methods triangulate what WST is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$146.07
Method range
$42.44 – $370.25
median $244.94
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $146.07 | -59.24% |
| Exit multiple | $343.80 | -4.08% |
| Analyst target | $370.25 | +3.30% |
| Graham number | $42.44 | -88.16% |
- Forward DCF$146.07
- Exit multiple$343.80
- Analyst target$370.25
- Graham number$42.44
Stock price
$358.41
FCF / share (TTM)
$0.66
3Y FCF CAGR
10.5%
Fair value @ hist. growth
$14.98
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied FCF growth
57.1%
per year over your projection horizon
Margin of safety -2,292.2% vs hist-growth DCF
Historical 3Y CAGR
10.5%
Your model implies
57.1%
Analyst consensus is EPS-only — no comparable FCF / share estimate to show on this basis.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Undiscounted FCF per share over 10 years at 10% annual growth.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 8.5% | 52.7% | 51.6% | 50.5% | 49.3% | 48.0% |
| 9.5% | 55.8% | 54.9% | 53.9% | 52.9% | 51.8% |
| 10.5% | 58.8% | 58.0% | 57.1% | 56.2% | 55.2% |
| 11.5% | 61.6% | 60.9% | 60.1% | 59.3% | 58.4% |
| 12.5% | 64.3% | 63.6% | 62.9% | 62.2% | 61.4% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
PEG
5.94
Demanding vs growth
Net cash
$375M
Total debt − cash
Beta
1.16
Vs market benchmark
Frequently asked questions
West Pharmaceutical Services (WST) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.65% TTM
- Dividend Profile0.24% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History4 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.